3 Most Promising Cancer Drugs in Late-Stage Development
- Abemaciclib
EvaluatePharma projects the drug will generate sales of $1.8 billion by 2022, if approved.
The FDA granted priority review for abemaciclib in July as a treatment for advanced breast cancer.
- Epacadostat
could make over $1.7 billion in sales in 2022, according to EvaluatePharma's analysis
this drug will be used for several types of cancer including non-small-cell lung cancer, renal cancer, head and neck cancer, and bladder cancer.
- Apalutamide
will be top of the cancer drugs by 2022.The late-stage candidate is projected to pull in sales of $1.6 billion five years from now.
Apalutamide is in four late-stage clinical studies targeting prostate cancer.